MedPath

NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JOINT STOCK COMPANY

🇻🇳Vietnam
Ownership
-
Employees
-
Market Cap
-
Website

Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis

Phase 1
Active, not recruiting
Conditions
Chronic Kidney Disease
Interventions
Biological: Stimus
First Posted Date
2022-12-05
Last Posted Date
2022-12-05
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
43
Registration Number
NCT05636891
Locations
🇻🇳

NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam

A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

Phase 3
Active, not recruiting
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Anemia
Interventions
Biological: Stimus (NNG-DEPO)
First Posted Date
2022-10-19
Last Posted Date
2023-01-06
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
214
Registration Number
NCT05585645
Locations
🇻🇳

NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Phase 1
Completed
Conditions
Breast Cancer Recurrent
Breast Cancer Metastatic
Breast Cancer Female
Interventions
First Posted Date
2022-03-29
Last Posted Date
2022-03-29
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
50
Registration Number
NCT05301530
Locations
🇻🇳

19-8 Hospital, Hanoi, Vietnam

🇻🇳

HCMC Oncology Hospital, Ho Chi Minh City, Vietnam

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Phase 3
Completed
Conditions
Breast Cancer Metastatic
Breast Cancer Recurrent
Breast Cancer Female
Interventions
First Posted Date
2022-03-29
Last Posted Date
2023-02-27
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
128
Registration Number
NCT05301010
Locations
🇻🇳

19-8 Hospital, Hanoi, Vietnam

🇻🇳

HCMC Oncology Hospital, Ho Chi Minh City, Vietnam

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

Phase 3
Active, not recruiting
Conditions
SARS-CoV-2 Infection
COVID-19
Interventions
Biological: Placebo
Biological: Nanocovax
First Posted Date
2021-06-11
Last Posted Date
2022-11-04
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
13000
Registration Number
NCT04922788
Locations
🇻🇳

Military Medical Academy, Hanoi, Vietnam

A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

Phase 1
Conditions
COVID-19
Interventions
Biological: Nanocovax
Biological: Placebo
First Posted Date
2020-12-24
Last Posted Date
2020-12-29
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
620
Registration Number
NCT04683484
Locations
🇻🇳

Military Medical Academy, Hanoi, Ha Dong, Vietnam

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Phase 3
Completed
Conditions
Breast Cancer Female
Interventions
Drug: Neulastim
Drug: pegcyte
First Posted Date
2017-12-22
Last Posted Date
2018-01-02
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
128
Registration Number
NCT03381417
Locations
🇻🇳

Vietnam National Cancer Institute (Hospital K), Hanoi, Vietnam

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2017-12-18
Last Posted Date
2017-12-19
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
24
Registration Number
NCT03376503
Locations
🇻🇳

Vietnam National Cancer Institute (Hospital K), Hanoi, Vietnam

The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

Phase 1
Completed
Conditions
Hepatitis C
Interventions
Biological: Peginterferon lambda
First Posted Date
2014-02-14
Last Posted Date
2016-12-15
Lead Sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Target Recruit Count
60
Registration Number
NCT02063607
Locations
🇻🇳

The Military 108 Hospital, Hanoi, Vietnam

© Copyright 2025. All Rights Reserved by MedPath